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Abstract
Background: Werner syndrome is a progeroid disorder characterized by premature age-related phenotypes.
Although it is well established that autosomal recessive mutations in the WRN gene is responsible for Werner
syndrome, the molecular alterations that lead to disease phenotype remain still unidentified.
Results: To address whether epigenetic changes can be associated with Werner syndrome phenotype, we
analysed genome-wide DNA methylation profile using the Infinium MethylationEPIC BeadChip in the whole
blood from three patients affected by Werner syndrome compared with three age- and sex-matched healthy
controls. Hypermethylated probes were enriched in glycosphingolipid biosynthesis, FoxO signalling and insulin
signalling pathways, while hypomethylated probes were enriched in PI3K-Akt signalling and focal adhesion
pathways. Twenty-two out of 47 of the differentially methylated genes belonging to the enriched pathways
resulted differentially expressed in a publicly available dataset on Werner syndrome fibroblasts. Interestingly,
differentially methylated regions identified CERS1 and CERS3, two members of the ceramide synthase family.
Moreover, we found differentially methylated probes within ITGA9 and ADAM12 genes, whose methylation is
altered in systemic sclerosis, and within the PRDM8 gene, whose methylation is affected in dyskeratosis
congenita and Down syndrome.
Conclusions: DNA methylation changes in the peripheral blood from Werner syndrome patients provide new
insight in the pathogenesis of the disease, highlighting in some cases a functional correlation of gene
expression and methylation status.
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Introduction
Werner syndrome (WS) is a rare adult premature ageing
disease. Individuals affected by WS generally have a nor-
mal development until the third decade of life, when pre-
mature ageing phenotypes and symptoms begin to
manifest including premature greying or loss of hair, bird-
like faces, cataracts, sclerodermiform skin atrophy [1] and
skin ulcers [2]. Because of apparent similar skin changes,
WS is often misdiagnosed as systemic sclerosis (SSc) [3].
Particularly, WS represents an important part of the
differential diagnosis in patients who present with
scleroderma-like skin changes, as they share with SSc pa-
tients the main histological changes of skin. These include
replacement of the subcutaneous tissue by hyalinized con-
nective, hyalinized connective tissue in the lower dermis
and hyalinization and formation of aneurysms in the dermal
blood vessels [4, 5]. Otherwise, progeria, premature cataract,
type 2 diabetes mellitus, sensorineural hearing loss, prema-
ture atherosclerosis and dyslipidemia in WS besides the ab-
sence of anti-scleroderma antibodies may be helpful for the
differential diagnosis of WS [6]. WS is associated to an
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autosomal recessive mutation of Werner syndrome gene
(WRN) [7, 8]; up today, more than 50 different disease-
causing mutations in the WRN gene have been identified
[8]. The WRN gene encodes a 180-kDa nuclear protein
member of the RecQ subfamily of DNA and RNA helicases
[8, 9] with an intrinsic 3′ to 5′ DNA helicase activity [10].
DNA helicases are involved in many aspects of DNA me-
tabolism including transcription, replication and recombin-
ation [9]. Given its role as a 3′ to 5′ exonuclease and based
on interactions between this protein and Ku70/80 heterodi-
mer in DNA end processing, WRN plays a critical role in
the repair of DNA double-strand breaks [11]. Additionally,
recent studies suggest a role for WRN in maintaining DNA
telomere stability [10]. It is well known that defects in telo-
mere structure and/or function may have a strong impact
on human health, leading to premature ageing and a variety
of diseases [12, 13]. Overall, WRN protein is crucial in
maintaining genome structure and integrity, and accord-
ingly, WS patients exhibit early age-associated biomarkers
like DNA damage accumulation and chromosomal instabil-
ity [14]. Despite these evidences, the molecular bases of WS
phenotype are still largely unknown.
Alterations in epigenetic patterns, in particular in DNA
methylation profiles, could contribute to WS phenotype.
DNA methylation, which consists in the addition of a me-
thyl group to the cytosine in a CpG dinucleotide, is a key
mechanism in development and differentiation, and pro-
found changes in DNA methylation patterns occur during
ageing and age-related diseases [15, 16]. At present, few
studies assessed DNA methylation changes in WS. Heyn
and colleagues evaluated genome-wide DNA methylation
in lymphoblastoid cell lines (LCLs) derived from Epstein-
Barr virus (EBV)-immortalized B cells of four WS patients
and three healthy controls [7], observing profound DNA
methylation changes in WS. More recently, a WRN pro-
moter was found hypermethylated in naïve B lymphocytes
and lymphoblastoid cell lines from two brothers carrying a
novel homozygous WRN mutation. Finally, Maierhofer et
al. applied Horvath’s epigenetic clock to a dataset including
the whole blood from WS patients and age-matched con-
trols, demonstrating that the disease is associated with an
increase in epigenetic age [17].
In the present study, we analysed genome-wide DNA
methylation in the peripheral whole blood from three WS
patients and their age- and sex-matched controls using
the Infinium MethylationEPIC BeadChip. Our results in-
dicate that specific genome-wide alterations occur in WS,
which partially overlap those that occur in diffuse and lim-
ited SSc [18].
Methods
Samples
Subjects were enrolled in the study “Early diagnosis of
scleroderma and identification of predictor factors of
disease development”. The study was approved by the Ethic
Committee of ASL RM/B, and all participants signed the
informed consent forms. WS was diagnosed according to
clinical appearance and genetic testing. Two patients were
siblings and carried the mutation c.2630+1G>A in the
WRN coding sequence; the third patient carried the homo-
zygous g.nt 77177 a>g mutation (GenBank acc. no.
AY44237) in the WRN gene. They suffer of skin ulcers of
suspected SSc derivation as they showed typical SSc skin
signs being bound tightly to the underlying tissues and
around joints causing an inability to pinch or lift the skin
up (Fig. 1a) and calcinosis cutis, a type of calcinosis which
characterized scleroderma skin ulcers [19–21] (Fig. 1b).
Serum was collected, and anti-nuclear antibodies (ANAs)
were analysed using indirect immunofluorescence (IIF) as-
says on ANA-HEp-2 cells (A. Menarini Diagnostics) ac-
cording to the manufacturer’s protocol. Anti-extractable
nuclear antigen (ENA) antibodies [anti-Sjögren’s syndrome
A (SS-A), anti-Sjögren’s syndrome B (SS-B), anti-Smith
(SM), anti-ribonucleoprotein (RNP), anti-topoisomerase I
(SCL-70) and anti-histidyl-tRNA synthetase (JO-1)] were
also dosed using chemiluminescence assay (Zenit RA auto-
immunity, A. Menarini Diagnostics) according to the man-
ufacturer’s protocol. These autoantibodies, considered as
SSc diagnostic markers, were undetectable in selected pa-
tients (data not shown). SSc patients were also subjected to
nailfold video capillaroscopy (NVC). Capillaroscopic alter-
ations and ectasias compatible with diagnosis of acrocyan-
osis were detected in all three patients (Fig. 1c). Peripheral
blood was collected from the three patients.
Genome-wide DNA methylation analysis
Genomic DNA was extracted from whole blood using the
Duplica® Blood DNA Kit (EuroClone) on Duplica® Prep
Platform (EuroClone). DNA was bisulfite-converted using
the EZ DNA Methylation-Gold Kit (Zymo Research) and
analysed using the Infinium HumanMethylationEPIC Bead-
Chip (Illumina) following the manufacturer’s instructions.
Signal intensity files were extracted using the minfi Biocon-
ductor package. Normalization was performed using the
functional normalization function implemented in minfi.
DNA methylation data are available at the NCBI Gene Ex-
pression Omnibus (GEO) database (http://www.ncbi.nlm.-
nih.gov/geo/) under accession number GSE100825.
DNA methylation differences between WS patients and
healthy controls were assessed using two different ap-
proaches: (1) we used analysis of variance (ANOVA) to
find out whether there was any statistically significant dif-
ference between WS patients and healthy controls when
we consider differentially methylated positions (DMPs),
that is single-CpG sites whose methylation differs between
the groups under investigation. DMPs with a non-
adjusted P value < 0.001 were retained as significantly dif-
ferentially methylated. (2) We applied multivariate analysis
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of variance (MANOVA) on sliding windows including
three adjacent CpG sites as described in Bacalini et al. [15]
in order to identify statistically significantly differentially
methylated regions (DMRs), that is regions in which mul-
tiple adjacent CpG sites differ between the two groups
under investigation. This approach was applied only to the
CpG probes mapping in CpG-rich regions (CpG islands,
shores and shelves) associated to a gene. DMRs with a
non-adjusted P value < 0.001 and in which at least two ad-
jacent CpG sites had a minimum absolute DNA methyla-
tion difference of 0.3 were retained as significant.
Although a 0.15 threshold for mean DNA methylation dif-
ference is often suggested [22], here we preferred to use a
more stringent criterion, given the small sample size, in
order to provide a short, but more likely reproducible, list
of DMRs.
Infinium450k datasets GSE42865 and GSE75310 were
downloaded from the GEO database. GSE42865 includes
DNA methylation data from the LCL of three Hutchinson-
Gilford progeria syndrome patients, four WS patients and
three healthy patients, together with peripheral blood
mononuclear cells from three healthy subjects and naïve B
cells from three healthy subjects. We compared the four
WS patients and the three LCL controls by ANOVA.
GSE75310 includes DNA methylation data from four dys-
keratosis congenita (DKC) patients. To investigate DNA
methylation differences in DKC, we performed ANOVA
using as controls the same four GEO samples
(GSM796678, GSM796674, GSM796667 and GSM796671)
used in the original paper [23].
Pathway enrichment
Pathway analysis of differentially methylated genes and
gene clusters was performed with the publicly available
tool Enrichr (http://amp.pharm.mssm.edu/Enrichr) that
provides access to various gene set libraries [24, 25].
Enrichr currently contains annotated gene sets from 102
gene set libraries organized in eight categories. Details of
the gene set libraries in Enrichr can be found in previ-
ously published studies [24, 25]. Enrichment analysis
checks whether the input set of genes significantly
overlaps with annotated gene sets. Each gene set within
the Enrichr database is associated with a functional term
or an enrichment term such as a pathway, cell line or
disease. The output of Enrichr is ranked lists of terms,
one list for each gene set library. The most highly ranked
enrichment terms for the user’s input gene list provide
knowledge about the input list. We used the publicly
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway gene sets to identify the relatively enriched bio-
logical pathways and then extracted the enriched gene
sets for each pathway. We considered pathways as
enriched if their P value was lower than 0.05 and ranked
them using the combined score (CS). CS is a multiplica-
tion of the P value computed using Fisher’s exact test
with the z-score of the deviation from the expected rank.
In particular, c is equal to log (p) × z where c is the com-
bined score, p is the P value computed using Fisher’s
exact test and z is the z-score computed to assess the
deviation from the expected rank.
Differential gene expression analysis
In order to perform differential expression analysis, we
used shinyGEO (http://gdancik.github.io/shinyGEO/) [26],
a Web-based tool that allows a user to download the ex-
pression and sample data from a GEO dataset, select a
gene of interest and perform a survival or differential ex-
pression analysis using the available data [27]. For both
analyses, shinyGEO is able to generate R code, ensuring
that all analyses are reproducible. The tool is developed
using shiny, a Web-based application framework for R, a
language for statistical computing and graphics. Fold
change (FC) and P value are calculated by two-sample
Student’s t test for differential expression.
Results
We used the Infinium MethylationEPIC BeadChip to
compare whole blood genome-wide DNA methylation
profiles between three WS patients and three age- and
sex-matched controls (CTRs). We conducted principal
component analysis to identify major traits of variation
between samples (Additional file 1: Figure S1). No clear
Fig. 1 SSc typical skin signs in WS patients. a Skin unable to be lifted in pliers and/or pinched. b Cutaneous ulcer with calcinosis. c Capillaroscopic
alterations and ectasias
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separation between WS patients and CTRs was observed
along the first component (which explained 32% of the
variance) or the second component (which explained 51%
of the remaining variance).
ANOVA identified 1125 DMPs that distinguished WS
patients from CTRs (non-adjusted P value < 0.001) (Fig. 2a,
Additional file 2, Table 1). Of these, 511 probes (mapping
in 382 genic regions) were hypermethylated and 614 probes
(mapping in 416 genic regions) were hypomethylated in
WS patients compared to CTRs. Several DMPs showed
large DNA methylation differences between the two
groups, with 87/511 hypermethylated and 110/614 hypo-
methylated probes having mean methylation differences lar-
ger than 0.15 [22]. The volcano plot in Fig. 2a shows many
CpG sites with non-adjusted P values lower than 0.001 but
having low DNA methylation differences between the
groups. This behaviour might be related to the small num-
ber of analysed WS samples.
Next, we performed a gene set enrichment analysis in
order to examine in silico the biological functions of
DMPs in WS patients compared to CTR samples. To
this aim, we searched for the overrepresented biological
pathways associated with the differentially methylated
genes, using as input for the Enrichr tool the list of
genes associated with DMPs. Enrichr’s combined score,
a combination of the P value and z-score, was consid-
ered in order to prioritize enriched pathways (see
“Methods” for more details). As detailed in the Enrichr
manuscript [24], the combined score provides a com-
promise between both methods (P value and z-score)
and, in several benchmarks, has reported the best rank-
ing when compared with the other scoring schemes.
We took into account the most highly ranked enriched
pathways according to the combined score while we
considered significantly overrepresented pathways, those
showing a P value < 0.05. Results for enriched biological
pathways are shown in Table 2. The hypermethylated
genes in KEGG pathway enrichment analysis results
were associated with the enriched pathways with P value
< 0.05, including “glycosphingolipid biosynthesis (HSA-
00603)”, “FoxO signalling pathway (HSA-04068)” and
“insulin signalling pathway (HSA-04910)”. The hypo-
methylated genes were associated with the enriched
pathways with P value < 0.05, including “PI3K-Akt sig-
nalling (HSA-04151)” and “focal adhesion (HSA-04510)”.
Finally, we also used the pipeline reported by Bacalini
et al. [15] (see “Methods” for details) to identify differen-
tially methylated regions (DMRs) between WS patients
and CTRs. We found 27 DMRs with a non-adjusted P
value < 0.001 (Additional file 3, Additional file 4, Table
3), 20 of which were clearly hypermethylated in WS pa-
tients compared to CTRs. Even these 27 DMRs (corre-
sponding to 37 genes) were employed in the Enrichr
pathway analysis approach, revealing “sphingolipid me-
tabolism (HSA-00600)” and “sphingolipid signalling
pathway (HSA-04071)” among the most enriched path-
ways with P value < 0.05. Both pathways contain CERS3
and CERS1 genes, which are two members of the cer-
amide synthase family.
To assess if the epigenetic pattern that we described in
our WS cohort was reproducible in other WS DNA
methylation datasets, we compared our results with
those available from a publicly available dataset (GEO
accession ID: GSE42865). GSE42865 includes DNA
methylation data from LCL from four WS patients and
three CTRs, measured using the previous version of the
microarray, the Infinium450k BeadChip [7]. Of the 1125
DMPs identified in our analysis, 581 are included in the
Infinium450k design. Of these, only two probes were dif-
ferentially methylated between LCLs of WS patients and
Fig. 2 DNA methylation alterations in Werner syndrome. a Volcano plot of DMPs between WS patients and CTRs. The difference between mean
DNA methylation values in WS patients and in CTRs is plotted on the x-axis, while the non-adjusted P value for ANOVA between the two groups
is on the y-axis (− 1 × log10 scale). The green line corresponds to a non-adjusted P value of 0.001. b DNA methylation profile of the CpG island
located in the CERS3 gene
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CTRs with a comparable statistical threshold (non-ad-
justed P value < 0.001), while 30 probes were found dif-
ferentially methylated, considering a less stringent
threshold (non-adjusted P value < 0.05) (Additional file
2). To investigate the reason of this low reproducibility
of the data, we focused on the DMPs mapping in the
genes resulting from the pathway enrichment analysis
that are present in both the microarray versions. We in-
cluded in this analysis also the probes mapping in
CERS1 and CERS3 DMRs. As shown in Additional file 5,
DNA methylation in LCL showed a larger variation in
WS and/or CTR subjects, possibly as a consequence of
Table 1 List of the top 20 DMPs
Probe CHR MAPINFO Gene CpG island name Relation with respect
to the CpG island
Non-adjusted
P value
cg15294279 3 174,842,010 NAALADL2 – – 9.48E−10
cg26845082 3 13,555,664 – – – 6.75E−09
cg23432430 12 125,538,377 – chr12:125534060-125534527 S_Shelf 8.75E−09
cg00597723 5 158,691,793 UBLCP1 chr5:158690013-158690541 S_Shore 1.05E−08
cg13956086 7 2,434,521 – – – 1.08E−08
cg16995742 2 237,992,612 COPS8 chr2:237994004-237994876 N_Shore 1.19E−08
cg17779733 22 49,589,242 – – – 7.55E−08
cg06052372 16 83,967,808 – – – 1.04E−07
cg23928292 12 21,815,474 – – – 1.19E−07
cg10360725 8 144,139,316 – – – 3.31E−07
cg14782559 6 33,131,893 COL11A2 chr6:33129291-33129718 S_Shelf 5.19E−07
cg18673341 7 22,481,962 STEAP1B – – 5.28E−07
cg26822175 22 27,018,010 CRYBA4 – – 5.71E−07
cg08161337 22 45,814,116 RIBC2 – – 5.86E−07
cg22664298 5 128,795,827 ADAMTS19 chr5:128795503-128797417 Island 7.16E−07
cg13885829 1 17,482,041 – – – 7.98E−07
cg07584620 1 2,265,881 MORN1 chr1:2266007-2266432 N_Shore 8.00E−07
cg20757478 6 31,012,262 – – – 8.99E−07
cg17628377 5 180,121,337 – – – 1.03E−06
cg15865722 11 68,860,657 – – – 1.03E−06
Table 2 Gene set enrichment analysis details are reported for DPMs (hypo- and hypermethylated genes) and DMRs
Enriched pathways Pathway ID Overlap P value Combined score Overlapping genes
Hypermethylated probes Glycosphingolipid biosynthesis HSA-00603 3/14 0.001 2.29 ST3GAL1, GBGT1, ST3GAL2
FoxO signal pathway HSA-04068 8/133 0.003 2.60 MAPK10, USP7, AKT2, STAT3,
PTEN, FOXO3, SKP2, GABARAP
Insulin signalling pathway HSA-04910 8/139 0.004 2.49 MAPK10, PTPN1, SHC2, AKT2,
PRKAK1B, FASN, TSC2, CRKL
Hypomethylated probes PI3K-Akt signalling HSA_04151 16/341 0.006 3.46 CSF-1R, CDKN1B, TNXB, VWF,
LAMA1, FLT4, THBS1, PTK2,
LPAR5, PPP2R2B, PPP2R2D,
MAPK1, COL6A6, FGFR1,
BCL2L1, ITGA9
Focal adhesion HSA_04510 12/202 0.01 3.26 MAPK10, TNXB, VWF, ROCK2,
LAMA1, FLT4, PXN, MAPK1,
COL6A6, THBS1, PTK2, ITGA9
DMRs Sphingolipid metabolism HSA_00600 2/120 0.003 4.54 CERS3, CERS1
Sphingolipid signalling pathway HSA_047071 1/47 0.001 5.36 CERS3
Overlap indicates the number of hits from the differentially methylated gene sets compared to the KEGG gene set library, while “overlapping genes”
column contains names of these hits. Differentially expressed genes between normal and WS fibroblasts in Cheung HH dataset [30] are reported.
Enriched pathways were selected based on the P value. Combined score is a multiplication of the P value computed using Fisher’s exact test with
the z-score of the deviation from the expected rank (see “Methods” for details)
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the immortalization process [28]. Accordingly, DNA
methylation differences were observed between LCL and
naïve B cells (Additional file 5). It is therefore plausible
that low overlapping between the GSE42865 dataset and
ours is related to the different sources of genomic DNA
(LCL vs whole blood). Despite these differences, we
noted that several CpG sites showed the same trend in
DNA methylation changes between WS patients and
CTRs, in particular within the CERS3 DMR and in VWF
and FOXO3 genes.
Furthermore, we compared WS-related epigenetic
changes with those occurring in DKC, a premature ageing
disease associated to impaired telomere maintenance. We
exploited a publicly available Infinium450k dataset (GEO
accession ID: GSE75310) performed on the whole blood
from four DKC subjects [23]. Of the 581 WS-DMPs in-
cluded in the Infinium450k design, 14 were differentially
methylated in DKC with a comparable threshold (non-
adjusted P value < 0.001), but only three of them showed a
concordant DNA methylation change in the two diseases
(Additional file 2). Despite this, we noted that the list of
WS-DMPs included three CpG sites (cg27111250,
cg10129063 and cg27639662) mapping in the S_Shore of
the chr4:81109887-81110460 CpG island in the PR do-
main containing eight (PRDM8) genes and hypermethy-
lated in WS patients compared to CTRs. This is of
particular interest, as PRDM8 is hypermethylated in DKC,
aplastic anaemia (AA) [23] and Down syndrome [29], al-
though in a different region (spanning from the CpG is-
land chr4:81118137-81118603 to the CpG island
chr4:81119095-81119391).
Unfortunately, RNA was not available from the samples
included in our cohort and it was not possible to assess the
expression of the genes identified as differentially methyl-
ated. To overcome this limitation, we exploited the GEO
database in order to get more insight into the relationship
Table 3 List of the 27 DMRs
CHR CpG island name Relation with respect to the CpG island Gene Non-adjusted
P value
18 chr18:30349690-30352302 S_Shore KLHL14 1.70E−05
12 chr12:50297580-50297988 S_Shore FAIM2 0.00013152
6 chr6:33396050-33396296 S_Shelf SYNGAP1 0.000168391
5 chr5:110074605-110075223 N_Shore SLC25A46 0.000215085
22 chr22:46366726-46368726 S_Shore WNT7B 0.000233192
17 chr17:46620367-46621373 S_Shore HOXB2; HOXB-AS1 0.000244681
10 chr10:5930914-5932389 N_Shore ANKRD16; FBXO18 0.000261161
3 chr3:9811466-9811736 S_Shore CAMK1 0.000281325
2 chr2:129075197-129077639 Island HS6ST1 0.000292046
15 chr15:71145995-71146820 N_Shore LARP6; LRRC49 0.000302033
15 chr15:101084428-101085178 Island CERS3 0.000341282
6 chr6:143999154-143999667 N_Shore PHACTR2 0.000393635
6 chr6:166755812-166756510 S_Shore LOC100289495; SFT2D1 0.000423645
4 chr4:146540053-146540656 N_Shore MMAA 0.000441415
17 chr17:20059028-20060060 N_Shore SPECC1 0.000444431
6 chr6:31939730-31940559 S_Shore DXO; STK19 0.000488824
15 chr15:99791328-99792042 N_Shore TTC23; LRRC28 0.0004949
19 chr19:19006031-19007546 S_Shore GDF1; CERS1 0.000509929
22 chr22:20134462-20134705 S_Shelf LOC388849 0.000585452
19 chr19:19624954-19627258 Island NDUFA13; TSSK6 0.000650774
1 chr1:160990718-160991225 N_Shore F11R 0.000652612
6 chr6:33266302-33267582 N_Shore RGL2 0.000759464
8 chr8:117886284-117887319 S_Shore RAD21-AS1; RAD21; MIR3610 0.000773036
19 chr19:35491151-35492020 N_Shore GRAMD1A 0.000798561
17 chr17:4692249-4693977 N_Shore GLTPD2 0.000853965
4 chr4:9783035-9784960 Island DRD5 0.000911924
4 chr4:1396291-1401730 Island NKX1-1 0.000928038
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between DNA methylation changes and WS features. We
selected the genes emerged from the pathway enrichment
analysis, and we checked their expression in a dataset in-
cluding ten WS and ten CTR skin fibroblasts (GEO acces-
sion ID: GSE48761) [30]. Enrichment analysis checks
whether an input set of genes significantly overlaps with an-
notated gene sets. We found 47 genes overlapping with the
annotated gene set from KEGG pathways (see the overlap
column in Table 1), and 22 out of 47 of these genes were
differentially expressed between WR patients and CTRs (P
value < 0.05), as reported in Fig. 3 and Additional file 6: Fig-
ure S2. The relationship between DNA methylation and ex-
pression changes is reported in Additional file 7. Focusing
on the DMRs, HS6ST1 was hypermethylated in the whole
blood from WS patients and downregulated in WS fibro-
blasts, while both CERS1 and CERS3 were hypermethylated
in the whole blood from WS patients and upregulated in
WS fibroblasts. Interestingly, we also noted that PRDM8
gene expression is downregulated in WS fibroblasts (data
not shown), like it was previously reported in the whole
blood from DKC patients [30]. Although further investiga-
tion is needed, possibly on the same biological specimen
from the same subject, these data underline an association
between deregulation of DNA methylation and gene ex-
pression in healthy donors and patients.
Discussion
In this study, we analysed genome-wide DNA methylation
in the peripheral blood from three WS subjects and three
age- and sex-matched controls, identifying 1125 DMPs
and 27 DMRs. Pathway enrichment analysis on the list of
hypermethylated and hypomethylated DMPs and on the
list of DMR provided interesting hints on the epigenetic
alterations in WS patients, possibly related with the dis-
ease phenotype. Bioactive sphingolipids have been sug-
gested to play a role in ageing and cellular senescence, and
in WS, lipid profile is often abnormal [31]. Moreover, gly-
cosphingolipids are elevated during ageing in the mouse
brain and liver as well as in human fibroblasts obtained
from elderly individuals [32]. On the other hand, longevity
is associated with genetic variation in insulin-FOXO path-
ways [33] and the signalling pathway connecting insulin
and FoxO transcription factors provides the most compel-
ling example for a conserved genetic pathway at the inter-
face between ageing and cancer. FoxO proteins are a
subgroup of the forkhead family of transcription factors,
which regulate the expression of genes involved in several
physiological events including apoptosis, cell cycle control,
glucose metabolism, oxidative stress resistance and lon-
gevity [34, 35]. In response to insulin or growth factors,
the protein is phosphorylated by Akt, downstream of
PI3K. This constitutes a signal to export FoxO from the
nucleus to the cytoplasm, thereby decreasing the expres-
sion of FoxO target genes [34, 36]. Dysregulation of the
insulin/PI3K/Akt pathway is implicated in several human
diseases including cancer, diabetes, cardiovascular diseases
and neurological diseases [37, 38]. Insulin signalling path-
way regulates ageing in many organisms, ranging from
simple invertebrates to mammals, including human [36].
Notably, the enrichment of hypermethylated probes in in-
sulin and FoxO signalling pathways is also consistent with
the clinical and metabolic evidences that relate WS to dis-
orders of lipid and liver function [39].
The hypomethylated probes were enriched in PI3K-Akt
signalling (HSA-04151) and focal adhesion (HSA-04510)
pathways. Even these results underline the importance of
deregulated methylation positions we detected. In fact, the
role of the PI3K/Akt/FoxO signalling in longevity appears
to be well conserved across species [40] and senescence-
related morphological alteration is one of the main features
of the senescent phenotype and it is deeply dependent to
changes of cellular structural determinants in terms of their
levels and activities. These determinants included integrins,
focal adhesion complexes and small Rho GTPases [41].
Importantly, the alteration of the above-mentioned
pathways in WS was fully supported when we correlated
gene sets detected as differentially methylated and a publicly
available gene expression dataset on WS fibroblasts
Fig. 3 Differential expression of CERS1, CERS3, ITGA9 and ADAM12 genes based on the publicly available dataset on WS fibroblast analyses
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including ten WS and ten CTR [30]. Indeed, several of the
differentially methylated genes belonging to the enriched
pathways showed altered RNA expression in fibroblasts
from WS patients compared to healthy controls (Fig. 3,
Additional file 6: Figure S2).
The small overlap between WS and DKC DMPs sug-
gests that the two progeroid diseases show distinct pat-
terns of epigenetic alterations. However, the PRDM8 gene
resulted hypermethylated in both WS and DKC, although
in different CpG sites, suggesting that epigenetic remodel-
ling in different premature ageing syndromes can con-
verge on the same gene.
Interestingly, the gene ITGA9, which encodes for an
alpha integrin, was previously reported to be hypomethy-
lated and overexpressed in fibroblasts from patients with
diffuse and limited SSc compared to fibroblasts from
healthy controls [18]. Although in our dataset WS affected
the methylation of a distinct CpG site in the body of ITGA9
(cg22345769, which is not assessed in the study by Altorok
et al. [18], as included in the Infinium MethylationEPIC
and not in the Infinium450k microarray), it is noteworthy
that the methylation and mRNA level of the same gene is
altered in both the diseases. In fact, in our bioinformatics
analysis, we detected a fold change equal to 1.15 for the dif-
ferential expression of ITGA9 (P value = 0.037). Further-
more, we found that another gene is implicated in cell-cell
and cell-matrix interactions, ADAM12, that resulted hypo-
methylated both in WS and in diffuse and limited SSc [18]
and overexpressed (fold change equal to 1.3, P value = 0.022)
in WS with respect to CTR when we analysed the
GSE48761 dataset [30] (Fig. 3). ADAM12 is involved in the
process of fibrosis through enhancing TGF-β signalling
pathway [42, 43]. Of note, the peripheral blood from WS
patients shared the same hypomethylated CpG site in the
body of ADAM12 with SSc fibroblasts.
Finally, CERS3 was shown to exhibit differentially methyl-
ated status between WS patients and CTRs. A distinct ex-
pression profile was also found between normal and WS
fibroblasts in the GSE48761 dataset (Fig. 3) [30]. This gene
regulates sphingolipid synthesis and is involved in the syn-
thesis of ceramides with ultra-long-chain acyl moieties
(ULC-Cers), playing an important role in creating a barrier
for the epidermis from the environment [44]. A mutation
in CERS3 is responsible of autosomal recessive congenital
ichthyosis [45], and interestingly, scleroderma-like changes
have been described in different clinical variants of ichthy-
osis [46]. All these data are of particular interest as WS has
some features that are typical SSc signs like skin sclerosis
and calcification and ankle ulcerations [47, 48]. Indeed, skin
sclerosis is a hallmark of SSc and skin thickening represents
the definitive diagnostic criterion of SSc in the vast majority
of cases [19–21, 49]. Common to SSc subjects, WS patients
show SSc-like skin involvement, calcinosis and skin ulcers;
in particular, ulcers are present in 50% of WS patients and
are generally the main cutaneous symptom [50, 51]. Any-
way, the possibility for WS patients to be diagnosed as SSc
was avoided as, based on 2013 ACR/EULAR classification
criteria for SSc disease [52], serological analyses performed
on subjects enrolled in the present study for anti-ANA and
anti-ENA (anti-SS-A, anti-SS-B, anti-SM, anti-RNP, anti-
SCL-70 and anti-JO-1) antibodies resulted negative. The
presence of serum autoantibodies directed to multiple
intracellular antigens is considered the serological hallmark
of SSc [53].
The emerging connection in WS and SSc epigenetic al-
terations that we observed in this study could be related to
the fact that the WS patients that we analysed for genome-
wide DNA methylation were recruited in the framework of
a study on SSc. Although we cannot exclude a priori this
hypothesis, it is worth to note that (1) the CpG sites
cg17287034 in the ADAM12 gene and cg06679270 in the
CERS3 gene showed the same DNA methylation trend in
the GSE42865 dataset and in ours (we cannot check ITGA9
because the probe is missing in the Infinium450k design)
(Additional file 5) and (2) ITGA9, ADAM12 and CERS3
showed gene expression changes between WS and normal
fibroblasts according to the GSE48761 dataset. As in both
the publicly available studies WS patients were not selected
on the basis of a SSc-like phenotype, we can suggest that
SSc-related epigenetic changes are an intrinsic characteris-
tic of WS. Although further studies should confirm our
findings, they could be particularly interesting since recent
studies highlight that another progeroid disease, the
Hutchinson-Gilford progeria syndrome, is associated with
SSc-like skin changes [54, 55] and that SSc-associated fibro-
sis is considered as an accelerated ageing phenotype [56].
Conclusions
In summary, we identified for the first time genome-wide
DNA methylation changes in the peripheral blood from
WS patients, providing important new insight in the
pathogenesis of the diseases and emphasizing the potential
role of DNA methylation changes in Werner disorder.
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